Jessica Rueb, MD
Urogynecology and Reconstructive Pelvic Surgery · West Columbia, SCNPI 1497199400
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,758 of the $11,618 with a category attached, or 75.4%. 22 manufacturers reported payments, led by Medtronic at 49.4% of the total. 2025 is the largest year on record at $3,997, 4.4 times the $913 reported in 2019.
Across 256 payments — averaging $45.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$6K
- Escala Medical Inc.$2K
- Axonics, Inc.$1K
- Boston Scientific$1K
- Sumitomo Pharma America, Inc.$614
- Coloplast$227
- plus $1K from 16 others
Across 1 payment — averaging $710.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$710
What the payments were for
- Consulting fees$1,73615%
- Travel & lodging$1,12310%
- Food & beverage$8,75875%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 109 | $5,736 |
| Escala Medical Inc. | 4 | $1,748 |
| Axonics, Inc. | 37 | $1,067 |
| Boston Scientific | 20 | $1,019 |
| Sumitomo Pharma America, Inc. | 27 | $614 |
| Coloplast | 12 | $227 |
| AbbVie | 15 | $222 |
| Astellas Pharma US Inc | 6 | $207 |
| Femselect Inc. | 1 | $139 |
| Valencia Technologies Corporation | 4 | $110 |
| Coopersurgical, Inc. | 1 | $107 |
| Millicent US Inc | 4 | $82 |
| Rochester Medical Corporation | 3 | $61 |
| Hologic Sales And Service, LLC | 2 | $59 |
| Ambu Inc. | 2 | $43 |
| ABC Home Medical Supply, Inc. | 2 | $42 |
| Johnson & Johnson | 1 | $28 |
| 180 Medical, Inc. | 1 | $27 |
| Laborie Medical Technologies Corp. | 1 | $23 |
| Organon | 2 | $23 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Urovant Sciences Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$3,103
- Axonics$380
- NURO$236
- EnPlace$139
- GENERAL VASCULAR INTERVENTION$132
- Bulkamid$122
- MYRBETRIQ$117
- LithoVue$116
- ALLY II UPS$107
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in South Carolinato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 251 | $158,567 |
| MyrbetriqMirabegron | 236 | $132,821 |
| Estradiol | 325 | $20,079 |
| Mirabegron ErMirabegron | 36 | $14,386 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 109 | $6,547 |
| Clobetasol Propionate | 35 | $2,836 |
| ImvexxyEstradiol | 12 | $2,424 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 115 | $1,679 |
| Methenamine Hippurate | 22 | $1,314 |
| ValacyclovirValacyclovir Hcl | 11 | $770 |
| Solifenacin Succinate | 17 | $504 |
| Nystatin-TriamcinoloneNystatin/Triamcinolone Acet | 18 | $460 |
| Terconazole | 16 | $423 |
| Tamsulosin Hcl | 21 | $419 |
| Amitriptyline Hcl | 21 | $279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $614 | $158,567251 claims |
| Astellas Pharma US IncMyrbetriq | $207 | $132,821236 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in South Carolinaon file to place this against a meaningful peer group, so we don't.
Other urogynecology and reconstructive pelvic surgery in West Columbia
- Thomas GiudiceWest Columbia$418K
- Collin McKenzieWest Columbia$6K
- Eric RovnerCharleston$284K
- Janet Harris-HicksMyrtle Beach$283K
- Rebecca RinkoGreenville$9K
- Ronald GlinskiFlorence$8K
- Gerald TaylorCharleston$7K
- Thomas WheelerSpartanburg$6K
- Johnnie WrightColumbia$4K
- Haley McEvoyMount Pleasant$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.